• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetic and Biodistribution Studies of [F]-Taccalonolide: A Covalent Microtubule Stabilizer with Antitumor Efficacy.[F] - 他卡洛内酯的药代动力学和生物分布研究:一种具有抗肿瘤功效的共价微管稳定剂
ACS Med Chem Lett. 2025 Jul 16;16(8):1569-1574. doi: 10.1021/acsmedchemlett.5c00208. eCollection 2025 Aug 14.
2
Synthesis, preclinical evaluation, and clinical translation of [Ga]Ga-Asp-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.用于神经内分泌肿瘤PET成像的SSTR2拮抗剂[镓]镓-天冬氨酸-JR11的合成、临床前评估及临床转化
Eur J Nucl Med Mol Imaging. 2025 Aug 30. doi: 10.1007/s00259-025-07474-x.
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer.Jab1调节HRR mRNA稳定性以调节三阴性乳腺癌中PARP抑制剂的敏感性。
Mol Cancer. 2025 Aug 16;24(1):217. doi: 10.1186/s12943-025-02422-7.
5
Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive Imaging of Triple-Negative Breast Cancer.用于三阴性乳腺癌无创成像的靶向神经纤毛蛋白-1的双模态PET/NIRF探针
Mol Pharm. 2025 Aug 4;22(8):4844-4854. doi: 10.1021/acs.molpharmaceut.5c00478. Epub 2025 Jul 1.
6
Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.靶向细胞外羟基磷灰石的新型药物肿瘤治疗:范式转变。
Cancer Med. 2024 Feb;13(3):e6812. doi: 10.1002/cam4.6812. Epub 2024 Jan 18.
7
A novel solid phase synthesis of an estradiol derivative and preclinical evaluation for targeting estrogen-receptor positive breast cancer.一种雌二醇衍生物的新型固相合成及其靶向雌激素受体阳性乳腺癌的临床前评估。
Sci Rep. 2025 Aug 17;15(1):30143. doi: 10.1038/s41598-025-15367-0.
8
Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer.伊伐布雷定可诱导RAD51降解,增强聚(ADP-核糖)聚合酶(PARP)抑制剂对非胚系BRCA致病变异三阴性乳腺癌的疗效。
J Transl Med. 2025 Aug 5;23(1):860. doi: 10.1186/s12967-025-06902-8.
9
Metabolic Targeting of Oxidative Phosphorylation Enhances Chemosensitivity in Triple-Negative Breast Cancer via a Synergistic Nanomedicine.通过协同纳米药物对氧化磷酸化进行代谢靶向可增强三阴性乳腺癌的化疗敏感性。
Theranostics. 2025 Jun 23;15(15):7607-7626. doi: 10.7150/thno.116250. eCollection 2025.
10
ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [Cu]Cu-NOTA-Trodelvy-F(ab').使用[铜]Cu-NOTA-Trodelvy-F(ab')对三阴性乳腺癌中Trop2表达进行免疫正电子发射断层扫描成像
Eur J Nucl Med Mol Imaging. 2025 Feb 25. doi: 10.1007/s00259-025-07167-5.

本文引用的文献

1
Taccalonolides: Structure, semi-synthesis, and biological activity.紫杉叶素内酯:结构、半合成及生物活性。
Front Pharmacol. 2022 Aug 11;13:968061. doi: 10.3389/fphar.2022.968061. eCollection 2022.
2
Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.共价微管稳定剂在紫杉烷耐药卵巢癌模型中的疗效。
Molecules. 2021 Jul 3;26(13):4077. doi: 10.3390/molecules26134077.
3
Taccalonolides: A Novel Class of Microtubule-Stabilizing Anticancer Agents.他卡缩醇内酯类:一类新型的微管稳定抗癌剂。
Cancers (Basel). 2021 Feb 22;13(4):920. doi: 10.3390/cancers13040920.
4
Taccalonolide Microtubule Stabilizers.他克林囊泡转运抑制剂
Prog Chem Org Nat Prod. 2020;112:183-206. doi: 10.1007/978-3-030-52966-6_3.
5
Triple-negative breast cancer molecular subtyping and treatment progress.三阴性乳腺癌分子分型及治疗进展。
Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
6
Elucidating target specificity of the taccalonolide covalent microtubule stabilizers employing a combinatorial chemical approach.采用组合化学方法阐明塔卡隆内酯共价微管稳定剂的靶标特异性。
Nat Commun. 2020 Jan 31;11(1):654. doi: 10.1038/s41467-019-14277-w.
7
Emerging Novel Therapeutics in Triple-Negative Breast Cancer.三阴性乳腺癌的新兴治疗策略。
Adv Exp Med Biol. 2019;1152:377-399. doi: 10.1007/978-3-030-20301-6_20.
8
Crystal Structure of the Cyclostreptin-Tubulin Adduct: Implications for Tubulin Activation by Taxane-Site Ligands.环孢菌素-微管蛋白加合物的晶体结构:对紫杉烷结合位点配体激活微管蛋白的影响。
Int J Mol Sci. 2019 Mar 20;20(6):1392. doi: 10.3390/ijms20061392.
9
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.单细胞测序描绘三阴性乳腺癌的化疗耐药演变。
Cell. 2018 May 3;173(4):879-893.e13. doi: 10.1016/j.cell.2018.03.041. Epub 2018 Apr 19.
10
Taccalonolide Microtubule Stabilizers Generated Using Semisynthesis Define the Effects of Mono Acyloxy Moieties at C-7 or C-15 and Disubstitutions at C-7 and C-25.使用半合成方法生成的塔卡醇内酯微管稳定剂定义了 C-7 或 C-15 的单烷氧基部分和 C-7 和 C-25 的双取代基的作用。
J Nat Prod. 2018 Mar 23;81(3):579-593. doi: 10.1021/acs.jnatprod.7b00967. Epub 2018 Jan 23.

[F] - 他卡洛内酯的药代动力学和生物分布研究:一种具有抗肿瘤功效的共价微管稳定剂

Pharmacokinetic and Biodistribution Studies of [F]-Taccalonolide: A Covalent Microtubule Stabilizer with Antitumor Efficacy.

作者信息

Jaskowski Luke N, Clanton Nicholas A, Wilkinson Nancy J, Bartels Jennifer L, LoCoco Peter M, Frantz Amber N, Boyer Andrew D, Boerma Joseph W, Bush Jycole E M, Brown Seth D, Fernandez Kayylen, Archer Noel E, Tekin Volkan, Fernandez Solana R, Risinger April L, Frantz Doug E, Lapi Suzanne E

机构信息

Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.

Voelcker Preclinical Pharmacology Core, University of Texas at San Antonio, San Antonio, Texas 78249, United States.

出版信息

ACS Med Chem Lett. 2025 Jul 16;16(8):1569-1574. doi: 10.1021/acsmedchemlett.5c00208. eCollection 2025 Aug 14.

DOI:10.1021/acsmedchemlett.5c00208
PMID:40843363
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12366129/
Abstract

The taccalonolides are plant-derived microtubule stabilizers that covalently and specifically bind β-tubulin and provide antitumor efficacy in drug-resistant tumor models both in vitro and in vivo. Herein, we report the radiolabeling, in vitro uptake, and in vivo imaging of a F radiolabeled taccalonolide to investigate in vivo biodistribution, including accumulation in TNBC tumors. Biochemical and cellular studies demonstrate that fluorination does not alter biological activity and supports target engagement of the radiolabeled compound. In vivo studies in athymic nude mice bearing TNBC xenografts and healthy control animals show the highest uptake in the gallbladder and intestines with modest uptake in tumors. Unmodified free drug was detected in the gall bladder and intestines, suggesting hepatic transport of the compound prior to metabolism or irreversible target engagement. These results provide a strong rationale for the generation of novel derivatives and formulations to improve serum half-life and tumor targeting of the taccalonolides to ultimately provide new options for drug-resistant TNBC tumors.

摘要

他卡诺内酯是植物来源的微管稳定剂,可与β-微管蛋白共价且特异性结合,并在体外和体内的耐药肿瘤模型中发挥抗肿瘤功效。在此,我们报告了一种氟放射性标记的他卡诺内酯的放射性标记、体外摄取及体内成像情况,以研究其体内生物分布,包括在三阴性乳腺癌(TNBC)肿瘤中的蓄积。生化和细胞研究表明,氟化不会改变生物活性,并支持放射性标记化合物与靶点的结合。在携带TNBC异种移植瘤的无胸腺裸鼠和健康对照动物中进行的体内研究显示,胆囊和肠道摄取量最高,肿瘤摄取量适中。在胆囊和肠道中检测到未修饰的游离药物,这表明该化合物在代谢或不可逆的靶点结合之前先经肝脏转运。这些结果为开发新型衍生物和制剂以改善他卡诺内酯的血清半衰期和肿瘤靶向性提供了有力依据,最终为耐药TNBC肿瘤提供新的治疗选择。